India's Sun Pharma plans $1 billion local debt sale for loan takeout
Sun Pharmaceutical pursued an acquisition with Sept 29 in focus.
29 Sept 2026 · BS Companies, NDTV Profit, LiveMint Companies
MUMBAI, Sept 29 (Reuters) - India's Sun Pharmaceutical Industries is planning to raise around 100 billion rupees ($1.04 billion) via a upee-denominated debt sale to partly fund a bridge loan it took to acquire US healthcare firm Organon & Co., three sources said on Tuesday.
Key facts
- Dates in focus
- Sept 29
The analysis
Against that, the stock is -1.7% on the day at ₹1,773.90, and has returned -6.2% over three months. It sits 11% below its 52-week high. The pharma & healthcare sector has moved -0.7% over the same period, so Sun Pharmaceutical is running 5.5 points behind its peers.
For Sun Pharmaceutical, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Market context
- The company directly in focus is SUNPHARMA.
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Buy, Sell Or Hold: HDFC Bank, Sun Pharma, Rallis India, Trent | Ask Profit
Taking Stock: Market fails to hold on to day#39;s gains, ends marginally higher
Market wrap: ITC, BSE, HCL Tech, Asian Paints top gainers and losers on Nifty and Sensex on Monday
Stock Market Today LIVE: Sensex Rises 500 Points, Nifty 50 Holds 22,700; India VIX Leaps 7%; Trent Rallies 12%
Last line of defence! How 7 Nifty stocks survived the market’s two-month bloodbath